Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7125131 | 0.89 | EPHX2 (0.49) | EPHX2NPC1RAB9AEGLN1ALDH1A1 | |
| SCHEMBL7124402 | 0.86 | BRAF (0.40) | RAB9ACHRNB2CHRNA4ALDH1A1CHRNA7 | |
| SCHEMBL7127598 | 0.86 | EPHX2 (0.39) | EPHX2NPC1RAB9AEGLN1CNR1 | |
| SCHEMBL7113610 | 0.85 | BRAF (0.37) | CHRNB2CHRNA4LMNAL3MBTL1CHRNA7 | |
| SCHEMBL7115118 | 0.85 | CHEK2 (0.36) | NPC1RAB9ACHRNA7 | |
| SCHEMBL7114448 | 0.83 | KDR (0.41) | RAB9ACHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL7127540 | 0.83 | EPHX2 (0.40) | EPHX2NPC1RAB9AEGLN1CNR1 | |
| SCHEMBL7122459 | 0.83 | SLC6A2 (0.37) | GRM5 | |
| SCHEMBL7115237 | 0.82 | CHRNA7 (0.37) | EPHX2NPC1RAB9AEGLN1CTSC | |
| SCHEMBL7125132 | 0.81 | EPHX2 (0.35) | EPHX2NPC1RAB9AEGLN1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | claimed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CYP7B1, UGT2B7, CYP1B1 | EPHX2 194/4885NPC1 267/4885RAB9A 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.